Marco Del Chiaro
Concepts (574)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 161 | 2025 | 875 | 32.550 |
Why?
| Pancreatectomy | 69 | 2025 | 241 | 16.940 |
Why?
| Carcinoma, Pancreatic Ductal | 67 | 2025 | 269 | 16.510 |
Why?
| Pancreaticoduodenectomy | 32 | 2025 | 158 | 6.920 |
Why?
| Adenocarcinoma | 28 | 2025 | 889 | 6.370 |
Why?
| Neoadjuvant Therapy | 28 | 2025 | 378 | 5.530 |
Why?
| Pancreas | 38 | 2024 | 304 | 4.400 |
Why?
| Adenocarcinoma, Mucinous | 16 | 2024 | 73 | 3.810 |
Why?
| Mesenteric Veins | 7 | 2025 | 18 | 3.120 |
Why?
| Pancreatic Cyst | 11 | 2024 | 51 | 2.750 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 1559 | 2.340 |
Why?
| Pancreatic Fistula | 11 | 2023 | 27 | 2.250 |
Why?
| Portal Vein | 11 | 2025 | 108 | 2.240 |
Why?
| Ampulla of Vater | 7 | 2025 | 39 | 2.130 |
Why?
| Common Bile Duct Neoplasms | 6 | 2025 | 27 | 2.090 |
Why?
| Carcinoma, Papillary | 9 | 2021 | 76 | 2.010 |
Why?
| Retrospective Studies | 88 | 2025 | 14532 | 1.870 |
Why?
| Pancreatic Ducts | 10 | 2022 | 79 | 1.860 |
Why?
| Humans | 238 | 2025 | 129527 | 1.850 |
Why?
| CA-19-9 Antigen | 4 | 2024 | 22 | 1.770 |
Why?
| Aged | 86 | 2025 | 22063 | 1.720 |
Why?
| Exocrine Pancreatic Insufficiency | 5 | 2019 | 20 | 1.620 |
Why?
| Prognosis | 30 | 2025 | 3772 | 1.610 |
Why?
| Survival Rate | 22 | 2025 | 1870 | 1.530 |
Why?
| Early Detection of Cancer | 6 | 2021 | 371 | 1.520 |
Why?
| Middle Aged | 93 | 2025 | 31087 | 1.460 |
Why?
| Neoplasm Recurrence, Local | 6 | 2024 | 956 | 1.440 |
Why?
| Gastrointestinal Neoplasms | 2 | 2023 | 72 | 1.410 |
Why?
| Vascular Surgical Procedures | 4 | 2025 | 295 | 1.350 |
Why?
| Mesenteric Artery, Superior | 4 | 2020 | 15 | 1.330 |
Why?
| Pancreas Transplantation | 24 | 2010 | 75 | 1.320 |
Why?
| Postoperative Complications | 30 | 2025 | 2475 | 1.230 |
Why?
| Male | 109 | 2025 | 63586 | 1.190 |
Why?
| Aged, 80 and over | 43 | 2025 | 7052 | 1.190 |
Why?
| Pancreatitis, Chronic | 6 | 2020 | 51 | 1.160 |
Why?
| Treatment Outcome | 40 | 2025 | 10232 | 1.090 |
Why?
| Female | 105 | 2025 | 68650 | 1.070 |
Why?
| Quality of Life | 8 | 2025 | 2694 | 1.070 |
Why?
| Islets of Langerhans | 5 | 2020 | 790 | 1.010 |
Why?
| Carcinoma, Neuroendocrine | 2 | 2023 | 32 | 1.000 |
Why?
| Chemotherapy, Adjuvant | 13 | 2025 | 376 | 0.990 |
Why?
| Liver Neoplasms | 4 | 2024 | 635 | 0.990 |
Why?
| Endosonography | 5 | 2021 | 141 | 0.980 |
Why?
| Biomarkers, Tumor | 13 | 2024 | 1159 | 0.940 |
Why?
| Databases, Factual | 3 | 2024 | 1261 | 0.930 |
Why?
| Nomograms | 3 | 2022 | 47 | 0.930 |
Why?
| Precancerous Conditions | 3 | 2015 | 160 | 0.920 |
Why?
| Follow-Up Studies | 23 | 2024 | 4891 | 0.890 |
Why?
| Adult | 70 | 2025 | 35505 | 0.890 |
Why?
| Hepatoblastoma | 1 | 2024 | 42 | 0.880 |
Why?
| Duodenal Neoplasms | 3 | 2023 | 21 | 0.870 |
Why?
| Neoplasms, Cystic, Mucinous, and Serous | 3 | 2023 | 25 | 0.860 |
Why?
| Thrombelastography | 2 | 2024 | 150 | 0.850 |
Why?
| Minimally Invasive Surgical Procedures | 3 | 2020 | 175 | 0.780 |
Why?
| Risk Assessment | 11 | 2025 | 3255 | 0.720 |
Why?
| Surgical Stapling | 1 | 2021 | 14 | 0.720 |
Why?
| Absorbable Implants | 1 | 2021 | 35 | 0.710 |
Why?
| Fluorouracil | 10 | 2025 | 197 | 0.710 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 197 | 0.700 |
Why?
| Organ Transplantation | 2 | 2023 | 228 | 0.690 |
Why?
| Neoplasm Staging | 12 | 2024 | 1281 | 0.690 |
Why?
| Cystadenocarcinoma, Mucinous | 2 | 2018 | 14 | 0.680 |
Why?
| Neoplasms, Second Primary | 2 | 2019 | 106 | 0.680 |
Why?
| Leucovorin | 7 | 2025 | 70 | 0.670 |
Why?
| Neoplasm Invasiveness | 7 | 2020 | 481 | 0.670 |
Why?
| Sweden | 6 | 2025 | 93 | 0.670 |
Why?
| Vascular Neoplasms | 1 | 2020 | 17 | 0.660 |
Why?
| Neoplasms, Multiple Primary | 3 | 2015 | 55 | 0.660 |
Why?
| Arteries | 2 | 2019 | 266 | 0.650 |
Why?
| Pancreatitis | 5 | 2022 | 124 | 0.650 |
Why?
| Liver Transplantation | 4 | 2024 | 833 | 0.640 |
Why?
| Adenocarcinoma, Papillary | 2 | 2017 | 11 | 0.640 |
Why?
| Endocrine System Diseases | 1 | 2019 | 33 | 0.630 |
Why?
| Practice Guidelines as Topic | 4 | 2024 | 1510 | 0.630 |
Why?
| Neuroendocrine Tumors | 4 | 2023 | 99 | 0.610 |
Why?
| Cohort Studies | 12 | 2024 | 5423 | 0.580 |
Why?
| Europe | 8 | 2021 | 362 | 0.550 |
Why?
| Patient Compliance | 1 | 2021 | 567 | 0.550 |
Why?
| Evidence-Based Medicine | 5 | 2024 | 715 | 0.550 |
Why?
| Metabolomics | 2 | 2019 | 652 | 0.540 |
Why?
| Patient Selection | 9 | 2024 | 659 | 0.540 |
Why?
| Kidney Transplantation | 17 | 2016 | 669 | 0.530 |
Why?
| Living Donors | 3 | 2016 | 286 | 0.530 |
Why?
| Neoplasm Metastasis | 1 | 2019 | 609 | 0.520 |
Why?
| Hepatic Artery | 4 | 2020 | 58 | 0.520 |
Why?
| Celiac Artery | 4 | 2020 | 10 | 0.520 |
Why?
| Watchful Waiting | 1 | 2016 | 67 | 0.520 |
Why?
| Hepatitis B virus | 1 | 2016 | 36 | 0.500 |
Why?
| Pancreaticojejunostomy | 3 | 2022 | 8 | 0.500 |
Why?
| Prospective Studies | 15 | 2024 | 7150 | 0.490 |
Why?
| Hypothermia, Induced | 1 | 2016 | 76 | 0.480 |
Why?
| Disease Progression | 5 | 2022 | 2628 | 0.460 |
Why?
| Organ Sparing Treatments | 1 | 2015 | 32 | 0.460 |
Why?
| Survival Analysis | 12 | 2024 | 1270 | 0.460 |
Why?
| Pancreatic Diseases | 3 | 2020 | 71 | 0.460 |
Why?
| Adenoma | 3 | 2025 | 211 | 0.450 |
Why?
| Antineoplastic Agents | 6 | 2021 | 2044 | 0.440 |
Why?
| Risk Factors | 16 | 2024 | 9779 | 0.430 |
Why?
| Deoxycytidine | 8 | 2025 | 163 | 0.430 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 1001 | 0.430 |
Why?
| Carcinoma, Hepatocellular | 1 | 2016 | 270 | 0.430 |
Why?
| Japan | 5 | 2025 | 98 | 0.420 |
Why?
| Palliative Care | 3 | 2019 | 704 | 0.420 |
Why?
| Radiotherapy, Adjuvant | 2 | 2024 | 208 | 0.420 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2019 | 206 | 0.420 |
Why?
| Combined Modality Therapy | 5 | 2024 | 1201 | 0.410 |
Why?
| Cystadenocarcinoma | 1 | 2013 | 2 | 0.410 |
Why?
| Cystadenoma | 1 | 2013 | 3 | 0.410 |
Why?
| Stomach Neoplasms | 2 | 2024 | 97 | 0.400 |
Why?
| Robotics | 1 | 2014 | 92 | 0.400 |
Why?
| Tomography, X-Ray Computed | 10 | 2021 | 2503 | 0.400 |
Why?
| Autoimmune Diseases | 3 | 2021 | 428 | 0.390 |
Why?
| Cystadenoma, Serous | 3 | 2020 | 18 | 0.390 |
Why?
| Diabetes Mellitus | 3 | 2019 | 988 | 0.390 |
Why?
| Italy | 11 | 2013 | 98 | 0.390 |
Why?
| Incidence | 8 | 2019 | 2643 | 0.380 |
Why?
| Diagnosis, Differential | 8 | 2022 | 1422 | 0.370 |
Why?
| Peritoneal Neoplasms | 2 | 2024 | 86 | 0.370 |
Why?
| Dilatation, Pathologic | 3 | 2020 | 60 | 0.370 |
Why?
| Propensity Score | 3 | 2025 | 266 | 0.360 |
Why?
| Gastroenterology | 2 | 2023 | 177 | 0.350 |
Why?
| Risk | 5 | 2022 | 857 | 0.350 |
Why?
| Gamma Rays | 2 | 2021 | 54 | 0.340 |
Why?
| Magnetic Resonance Imaging | 8 | 2021 | 3392 | 0.340 |
Why?
| Neoplastic Syndromes, Hereditary | 1 | 2010 | 37 | 0.330 |
Why?
| Chemoradiotherapy | 2 | 2022 | 208 | 0.330 |
Why?
| Portal System | 6 | 2020 | 13 | 0.330 |
Why?
| Tissue Donors | 14 | 2005 | 391 | 0.330 |
Why?
| Microbiota | 3 | 2025 | 734 | 0.330 |
Why?
| Adolescent | 15 | 2022 | 20409 | 0.320 |
Why?
| Neoplasm Grading | 4 | 2020 | 283 | 0.320 |
Why?
| Decision Making | 1 | 2016 | 860 | 0.310 |
Why?
| Kidney | 2 | 2016 | 1382 | 0.310 |
Why?
| Lymphatic Metastasis | 3 | 2024 | 319 | 0.310 |
Why?
| Age Factors | 6 | 2022 | 3150 | 0.300 |
Why?
| Population Surveillance | 2 | 2019 | 440 | 0.300 |
Why?
| Young Adult | 11 | 2022 | 12438 | 0.300 |
Why?
| Benchmarking | 2 | 2020 | 175 | 0.300 |
Why?
| Mass Screening | 2 | 2019 | 1186 | 0.300 |
Why?
| Tumor Burden | 2 | 2022 | 287 | 0.290 |
Why?
| Software | 2 | 2017 | 608 | 0.290 |
Why?
| Predictive Value of Tests | 5 | 2024 | 1950 | 0.280 |
Why?
| Laparoscopy | 3 | 2021 | 446 | 0.280 |
Why?
| Graft Survival | 12 | 2005 | 514 | 0.280 |
Why?
| Genetic Predisposition to Disease | 6 | 2019 | 2271 | 0.270 |
Why?
| Islets of Langerhans Transplantation | 3 | 2020 | 63 | 0.270 |
Why?
| Internationality | 4 | 2020 | 150 | 0.270 |
Why?
| Disease-Free Survival | 5 | 2023 | 647 | 0.260 |
Why?
| Cytoreduction Surgical Procedures | 2 | 2024 | 59 | 0.260 |
Why?
| Family Health | 1 | 2007 | 198 | 0.260 |
Why?
| Drainage | 10 | 2022 | 164 | 0.260 |
Why?
| Pedigree | 3 | 2014 | 482 | 0.260 |
Why?
| Multidetector Computed Tomography | 2 | 2016 | 33 | 0.250 |
Why?
| Length of Stay | 5 | 2021 | 1132 | 0.250 |
Why?
| Observer Variation | 2 | 2024 | 314 | 0.250 |
Why?
| Cholangiocarcinoma | 2 | 2024 | 77 | 0.240 |
Why?
| Cyst Fluid | 2 | 2022 | 25 | 0.240 |
Why?
| Immunohistochemistry | 5 | 2019 | 1684 | 0.240 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 204 | 0.240 |
Why?
| Proportional Hazards Models | 4 | 2023 | 1196 | 0.230 |
Why?
| Mucosal-Associated Invariant T Cells | 1 | 2025 | 27 | 0.230 |
Why?
| Pylorus | 1 | 2024 | 17 | 0.230 |
Why?
| Chemoradiotherapy, Adjuvant | 3 | 2019 | 41 | 0.230 |
Why?
| Gallbladder Neoplasms | 1 | 2024 | 21 | 0.230 |
Why?
| Perioperative Care | 2 | 2024 | 165 | 0.230 |
Why?
| Spheroids, Cellular | 1 | 2025 | 76 | 0.220 |
Why?
| Time Factors | 10 | 2021 | 6530 | 0.220 |
Why?
| Prevalence | 3 | 2023 | 2561 | 0.210 |
Why?
| Lymph Node Excision | 1 | 2024 | 164 | 0.210 |
Why?
| Incidental Findings | 2 | 2021 | 80 | 0.210 |
Why?
| Bile Duct Neoplasms | 1 | 2024 | 99 | 0.210 |
Why?
| Metastasectomy | 1 | 2023 | 19 | 0.210 |
Why?
| Hyperemia | 1 | 2023 | 48 | 0.210 |
Why?
| Hospital Mortality | 4 | 2020 | 851 | 0.210 |
Why?
| Reoperation | 7 | 2018 | 542 | 0.200 |
Why?
| Pilot Projects | 5 | 2023 | 1594 | 0.200 |
Why?
| Surgical Oncology | 1 | 2022 | 22 | 0.200 |
Why?
| Hyperamylasemia | 1 | 2022 | 3 | 0.200 |
Why?
| STAT3 Transcription Factor | 2 | 2022 | 194 | 0.190 |
Why?
| Pancreatitis, Acute Necrotizing | 1 | 2022 | 12 | 0.190 |
Why?
| Forecasting | 1 | 2023 | 360 | 0.190 |
Why?
| Colonic Neoplasms | 1 | 2024 | 241 | 0.190 |
Why?
| Carcinoma, Acinar Cell | 1 | 2021 | 4 | 0.190 |
Why?
| Plastics | 1 | 2022 | 47 | 0.190 |
Why?
| Multicenter Studies as Topic | 1 | 2023 | 287 | 0.190 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2022 | 89 | 0.180 |
Why?
| Biliary Tract Surgical Procedures | 1 | 2021 | 25 | 0.180 |
Why?
| Pathology, Clinical | 1 | 2021 | 36 | 0.180 |
Why?
| Datasets as Topic | 1 | 2021 | 109 | 0.180 |
Why?
| Cysts | 1 | 2022 | 108 | 0.180 |
Why?
| Bacteria | 2 | 2025 | 812 | 0.180 |
Why?
| ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
| Surgical Mesh | 1 | 2021 | 46 | 0.180 |
Why?
| Fusobacterium nucleatum | 1 | 2020 | 3 | 0.170 |
Why?
| Fusobacterium Infections | 1 | 2020 | 7 | 0.170 |
Why?
| Netherlands | 3 | 2025 | 77 | 0.170 |
Why?
| Digestive System Surgical Procedures | 1 | 2021 | 98 | 0.170 |
Why?
| Body Composition | 1 | 2024 | 649 | 0.170 |
Why?
| Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.170 |
Why?
| Child, Preschool | 4 | 2024 | 10499 | 0.170 |
Why?
| Microdissection | 2 | 2011 | 15 | 0.170 |
Why?
| Oligonucleotides, Antisense | 1 | 2020 | 111 | 0.170 |
Why?
| Antimetabolites, Antineoplastic | 2 | 2010 | 91 | 0.170 |
Why?
| Blood | 1 | 2020 | 105 | 0.170 |
Why?
| Comorbidity | 2 | 2022 | 1548 | 0.160 |
Why?
| Radiation Injuries | 1 | 2021 | 135 | 0.160 |
Why?
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 64 | 0.160 |
Why?
| Antibodies, Bacterial | 1 | 2020 | 139 | 0.160 |
Why?
| Conservative Treatment | 1 | 2020 | 32 | 0.160 |
Why?
| Cyclosporine | 4 | 2005 | 263 | 0.160 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2020 | 68 | 0.160 |
Why?
| Dilatation | 1 | 2019 | 62 | 0.160 |
Why?
| Lasers | 2 | 2011 | 133 | 0.160 |
Why?
| Elective Surgical Procedures | 1 | 2020 | 165 | 0.150 |
Why?
| Biliary Tract Diseases | 1 | 2019 | 36 | 0.150 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2021 | 201 | 0.150 |
Why?
| Bacterial Infections | 1 | 2021 | 234 | 0.150 |
Why?
| Laparotomy | 2 | 2016 | 104 | 0.150 |
Why?
| Saliva | 1 | 2020 | 212 | 0.150 |
Why?
| Sensitivity and Specificity | 2 | 2021 | 1842 | 0.150 |
Why?
| Bile Ducts | 1 | 2019 | 68 | 0.150 |
Why?
| Mouth | 1 | 2019 | 84 | 0.150 |
Why?
| Referral and Consultation | 1 | 2024 | 732 | 0.150 |
Why?
| Organ Culture Techniques | 1 | 2019 | 155 | 0.150 |
Why?
| Patient Care Team | 3 | 2020 | 600 | 0.150 |
Why?
| Immunosuppressive Agents | 6 | 2005 | 858 | 0.150 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 1327 | 0.150 |
Why?
| Insulin | 8 | 2013 | 2313 | 0.150 |
Why?
| Nutritional Support | 1 | 2018 | 32 | 0.150 |
Why?
| DNA Damage | 1 | 2021 | 383 | 0.150 |
Why?
| Fibrosis | 1 | 2021 | 526 | 0.150 |
Why?
| Societies, Medical | 2 | 2020 | 757 | 0.150 |
Why?
| Iopamidol | 2 | 2016 | 16 | 0.150 |
Why?
| Recombinant Fusion Proteins | 4 | 2005 | 650 | 0.140 |
Why?
| Patient Acceptance of Health Care | 1 | 2024 | 761 | 0.140 |
Why?
| Jejunum | 2 | 2016 | 30 | 0.140 |
Why?
| Carcinoma | 1 | 2019 | 213 | 0.140 |
Why?
| Radiosurgery | 1 | 2020 | 321 | 0.140 |
Why?
| DNA, Bacterial | 1 | 2019 | 323 | 0.140 |
Why?
| Kaplan-Meier Estimate | 2 | 2016 | 850 | 0.140 |
Why?
| Logistic Models | 2 | 2020 | 1983 | 0.140 |
Why?
| Malnutrition | 1 | 2018 | 79 | 0.140 |
Why?
| Cross-Sectional Studies | 3 | 2024 | 5078 | 0.140 |
Why?
| Biliary Tract Neoplasms | 1 | 2016 | 25 | 0.130 |
Why?
| Hepatic Duct, Common | 1 | 2016 | 6 | 0.130 |
Why?
| Jaundice, Obstructive | 1 | 2016 | 2 | 0.130 |
Why?
| Hyperglycemia | 1 | 2020 | 325 | 0.130 |
Why?
| Epitopes | 1 | 2018 | 473 | 0.130 |
Why?
| Cholangiopancreatography, Magnetic Resonance | 1 | 2016 | 16 | 0.130 |
Why?
| Triiodobenzoic Acids | 1 | 2016 | 9 | 0.130 |
Why?
| Organ Preservation Solutions | 3 | 2005 | 45 | 0.130 |
Why?
| Cholangitis, Sclerosing | 1 | 2016 | 71 | 0.130 |
Why?
| Radiographic Image Enhancement | 1 | 2016 | 54 | 0.120 |
Why?
| Sex Factors | 1 | 2022 | 1966 | 0.120 |
Why?
| Cannabis | 1 | 2023 | 461 | 0.120 |
Why?
| Embolization, Therapeutic | 1 | 2018 | 207 | 0.120 |
Why?
| Machine Learning | 1 | 2020 | 441 | 0.120 |
Why?
| Printing, Three-Dimensional | 1 | 2016 | 88 | 0.120 |
Why?
| Bacteriocins | 1 | 2015 | 2 | 0.120 |
Why?
| Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| Hepatitis B | 1 | 2016 | 66 | 0.120 |
Why?
| Genes, BRCA2 | 1 | 2015 | 22 | 0.120 |
Why?
| Recovery of Function | 1 | 2019 | 644 | 0.120 |
Why?
| Coronavirus Infections | 1 | 2020 | 336 | 0.120 |
Why?
| Genes, BRCA1 | 1 | 2015 | 30 | 0.120 |
Why?
| Organ Preservation | 3 | 2004 | 94 | 0.120 |
Why?
| Interferon-gamma | 1 | 2018 | 773 | 0.120 |
Why?
| Surveys and Questionnaires | 4 | 2022 | 5429 | 0.120 |
Why?
| Diabetes Mellitus, Type 1 | 10 | 2010 | 3622 | 0.120 |
Why?
| Papilloma, Intraductal | 1 | 2014 | 3 | 0.120 |
Why?
| Heredity | 1 | 2014 | 12 | 0.120 |
Why?
| Genomics | 2 | 2017 | 715 | 0.110 |
Why?
| Membrane Proteins | 1 | 2021 | 1118 | 0.110 |
Why?
| Albumins | 2 | 2025 | 104 | 0.110 |
Why?
| Germany | 2 | 2024 | 100 | 0.110 |
Why?
| Amylases | 1 | 2013 | 16 | 0.110 |
Why?
| Risk Adjustment | 1 | 2014 | 78 | 0.110 |
Why?
| Neoplasm, Residual | 1 | 2014 | 121 | 0.110 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 486 | 0.110 |
Why?
| Apoptosis | 6 | 2021 | 2488 | 0.110 |
Why?
| Reproducibility of Results | 6 | 2019 | 3081 | 0.110 |
Why?
| Antibodies, Monoclonal | 4 | 2005 | 1366 | 0.110 |
Why?
| Tissue and Organ Harvesting | 5 | 2005 | 70 | 0.110 |
Why?
| Paclitaxel | 2 | 2025 | 217 | 0.110 |
Why?
| Perception | 1 | 2016 | 346 | 0.110 |
Why?
| Breast Neoplasms | 2 | 2024 | 2101 | 0.110 |
Why?
| Severity of Illness Index | 3 | 2019 | 2734 | 0.110 |
Why?
| Precision Medicine | 1 | 2017 | 385 | 0.110 |
Why?
| Virus Diseases | 1 | 2016 | 210 | 0.110 |
Why?
| Abdomen | 2 | 2004 | 119 | 0.110 |
Why?
| North America | 2 | 2024 | 294 | 0.110 |
Why?
| MicroRNAs | 2 | 2010 | 677 | 0.110 |
Why?
| Cell Proliferation | 5 | 2021 | 2367 | 0.100 |
Why?
| Tacrolimus | 2 | 2005 | 193 | 0.100 |
Why?
| Syndrome | 1 | 2014 | 338 | 0.100 |
Why?
| Cystadenoma, Mucinous | 1 | 2013 | 13 | 0.100 |
Why?
| Diagnostic Imaging | 1 | 2015 | 326 | 0.100 |
Why?
| Imaging, Three-Dimensional | 1 | 2016 | 530 | 0.100 |
Why?
| Cadaver | 8 | 2005 | 308 | 0.100 |
Why?
| Diagnostic Errors | 1 | 2014 | 162 | 0.100 |
Why?
| Immunotherapy, Adoptive | 1 | 2016 | 300 | 0.100 |
Why?
| ROC Curve | 3 | 2024 | 503 | 0.100 |
Why?
| Neoplasms | 2 | 2022 | 2450 | 0.100 |
Why?
| Insulin-Secreting Cells | 2 | 2007 | 367 | 0.100 |
Why?
| Endoscopy | 1 | 2014 | 290 | 0.100 |
Why?
| Catheter Ablation | 1 | 2015 | 336 | 0.090 |
Why?
| Practice Patterns, Physicians' | 1 | 2020 | 1257 | 0.090 |
Why?
| Preoperative Care | 1 | 2014 | 337 | 0.090 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2016 | 707 | 0.090 |
Why?
| C-Reactive Protein | 1 | 2013 | 400 | 0.090 |
Why?
| Loss of Heterozygosity | 1 | 2011 | 45 | 0.090 |
Why?
| Carcinoma in Situ | 1 | 2011 | 44 | 0.090 |
Why?
| Biomarkers | 1 | 2022 | 3968 | 0.090 |
Why?
| Graft Rejection | 5 | 2005 | 598 | 0.090 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2011 | 65 | 0.090 |
Why?
| United States | 3 | 2024 | 13865 | 0.090 |
Why?
| Lung Neoplasms | 1 | 2023 | 2342 | 0.080 |
Why?
| Raffinose | 3 | 2005 | 23 | 0.080 |
Why?
| Tissue and Organ Procurement | 2 | 2004 | 290 | 0.080 |
Why?
| Disaccharides | 3 | 2005 | 18 | 0.080 |
Why?
| Glucose | 3 | 2020 | 996 | 0.080 |
Why?
| Mannitol | 3 | 2005 | 38 | 0.080 |
Why?
| Allopurinol | 3 | 2005 | 62 | 0.080 |
Why?
| Histidine | 3 | 2005 | 60 | 0.080 |
Why?
| Glutamates | 3 | 2005 | 57 | 0.080 |
Why?
| Electrolytes | 3 | 2005 | 58 | 0.080 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2016 | 855 | 0.080 |
Why?
| Peptides | 1 | 2015 | 925 | 0.080 |
Why?
| Quality of Health Care | 1 | 2014 | 607 | 0.080 |
Why?
| Lymph Nodes | 2 | 2024 | 471 | 0.080 |
Why?
| Duodenum | 1 | 2010 | 74 | 0.080 |
Why?
| Cell Line, Tumor | 4 | 2025 | 3181 | 0.080 |
Why?
| Tumor Cells, Cultured | 2 | 2021 | 931 | 0.080 |
Why?
| Intra-Abdominal Fat | 1 | 2009 | 88 | 0.080 |
Why?
| Down-Regulation | 1 | 2011 | 631 | 0.070 |
Why?
| Adenosine | 3 | 2005 | 225 | 0.070 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2022 | 372 | 0.070 |
Why?
| Glutathione | 3 | 2005 | 349 | 0.070 |
Why?
| Magnetic Resonance Angiography | 1 | 2010 | 234 | 0.070 |
Why?
| Enzyme Replacement Therapy | 2 | 2018 | 13 | 0.070 |
Why?
| Germ-Line Mutation | 2 | 2019 | 140 | 0.070 |
Why?
| Morbidity | 2 | 2019 | 300 | 0.070 |
Why?
| Diabetic Retinopathy | 2 | 2006 | 179 | 0.070 |
Why?
| ErbB Receptors | 1 | 2010 | 605 | 0.070 |
Why?
| Gliclazide | 1 | 2007 | 2 | 0.070 |
Why?
| Clinical Decision-Making | 2 | 2020 | 304 | 0.070 |
Why?
| Cytotoxicity, Immunologic | 2 | 2018 | 220 | 0.070 |
Why?
| Hepatectomy | 2 | 2024 | 212 | 0.060 |
Why?
| Arterial Occlusive Diseases | 1 | 2007 | 80 | 0.060 |
Why?
| Consensus | 2 | 2020 | 622 | 0.060 |
Why?
| Equilibrative Nucleoside Transporter 1 | 1 | 2006 | 17 | 0.060 |
Why?
| Child | 4 | 2024 | 20932 | 0.060 |
Why?
| Extracorporeal Circulation | 1 | 2006 | 13 | 0.060 |
Why?
| Blood Loss, Surgical | 1 | 2007 | 96 | 0.060 |
Why?
| C-Peptide | 1 | 2007 | 155 | 0.060 |
Why?
| Hepatic Veins | 1 | 2006 | 31 | 0.060 |
Why?
| Tumor Microenvironment | 2 | 2020 | 627 | 0.060 |
Why?
| Lacerations | 1 | 2006 | 29 | 0.060 |
Why?
| Vena Cava, Inferior | 1 | 2006 | 68 | 0.060 |
Why?
| Alcohol Drinking | 2 | 2013 | 764 | 0.060 |
Why?
| Drug Resistance, Neoplasm | 1 | 2010 | 751 | 0.060 |
Why?
| Neovascularization, Pathologic | 1 | 2007 | 292 | 0.060 |
Why?
| Transplantation, Autologous | 1 | 2006 | 213 | 0.060 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 232 | 0.060 |
Why?
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 26 | 0.060 |
Why?
| Smoking | 2 | 2013 | 1501 | 0.060 |
Why?
| Abdominal Injuries | 1 | 2006 | 118 | 0.060 |
Why?
| Jehovah's Witnesses | 1 | 2004 | 3 | 0.060 |
Why?
| Bezoars | 1 | 2004 | 4 | 0.060 |
Why?
| Contrast Media | 3 | 2016 | 393 | 0.060 |
Why?
| RNA, Messenger | 5 | 2011 | 2697 | 0.050 |
Why?
| Anthropometry | 1 | 2024 | 203 | 0.050 |
Why?
| Biopsy | 3 | 2019 | 1087 | 0.050 |
Why?
| Intestinal Obstruction | 1 | 2004 | 49 | 0.050 |
Why?
| Splenectomy | 1 | 2024 | 58 | 0.050 |
Why?
| Chemotaxis | 1 | 2004 | 130 | 0.050 |
Why?
| Consensus Development Conferences as Topic | 1 | 2023 | 26 | 0.050 |
Why?
| Cystectomy | 1 | 2003 | 37 | 0.050 |
Why?
| Antioxidants | 1 | 2007 | 557 | 0.050 |
Why?
| Intestine, Small | 1 | 2004 | 151 | 0.050 |
Why?
| Intraoperative Complications | 1 | 2004 | 129 | 0.050 |
Why?
| Postoperative Period | 2 | 2019 | 329 | 0.050 |
Why?
| Ileum | 1 | 2003 | 116 | 0.050 |
Why?
| Wounds, Nonpenetrating | 1 | 2006 | 273 | 0.050 |
Why?
| Delphi Technique | 1 | 2024 | 227 | 0.050 |
Why?
| Gastrectomy | 1 | 2023 | 102 | 0.050 |
Why?
| Propylamines | 1 | 2022 | 11 | 0.050 |
Why?
| Genetic Testing | 1 | 2005 | 422 | 0.050 |
Why?
| Carbohydrates | 1 | 2022 | 64 | 0.050 |
Why?
| Stents | 2 | 2022 | 504 | 0.050 |
Why?
| Azathioprine | 1 | 2001 | 50 | 0.050 |
Why?
| Urinary Bladder | 1 | 2003 | 176 | 0.050 |
Why?
| Creatinine | 4 | 2004 | 489 | 0.050 |
Why?
| Vascular Diseases | 1 | 2004 | 240 | 0.050 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 952 | 0.040 |
Why?
| Necrosis | 1 | 2022 | 234 | 0.040 |
Why?
| Mycophenolic Acid | 1 | 2001 | 110 | 0.040 |
Why?
| Retroperitoneal Space | 3 | 2005 | 16 | 0.040 |
Why?
| Hernia, Inguinal | 1 | 2001 | 34 | 0.040 |
Why?
| Steroids | 1 | 2001 | 158 | 0.040 |
Why?
| Urinary Bladder Neoplasms | 1 | 2003 | 225 | 0.040 |
Why?
| Ephrin-B2 | 1 | 2021 | 50 | 0.040 |
Why?
| Endometriosis | 1 | 2001 | 46 | 0.040 |
Why?
| Endoscopy, Gastrointestinal | 1 | 2023 | 218 | 0.040 |
Why?
| Hyperplasia | 1 | 2021 | 175 | 0.040 |
Why?
| Case-Control Studies | 2 | 2022 | 3383 | 0.040 |
Why?
| Microbial Viability | 1 | 2021 | 83 | 0.040 |
Why?
| Medical Oncology | 1 | 2022 | 267 | 0.040 |
Why?
| Adipose Tissue | 1 | 2024 | 594 | 0.040 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 5468 | 0.040 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2020 | 86 | 0.040 |
Why?
| Mice | 3 | 2022 | 16973 | 0.040 |
Why?
| Capecitabine | 1 | 2019 | 45 | 0.040 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2005 | 577 | 0.040 |
Why?
| Secretin | 2 | 2010 | 4 | 0.040 |
Why?
| Florida | 1 | 2020 | 93 | 0.040 |
Why?
| Margins of Excision | 1 | 2019 | 38 | 0.040 |
Why?
| Republic of Korea | 1 | 2019 | 29 | 0.040 |
Why?
| Matched-Pair Analysis | 1 | 2019 | 39 | 0.040 |
Why?
| Asia | 1 | 2019 | 58 | 0.040 |
Why?
| Treatment Failure | 3 | 2005 | 339 | 0.040 |
Why?
| International Cooperation | 1 | 2020 | 177 | 0.040 |
Why?
| Cell Death | 1 | 2021 | 352 | 0.040 |
Why?
| Hyperthermia, Induced | 1 | 2020 | 108 | 0.040 |
Why?
| Acute Disease | 1 | 2022 | 975 | 0.040 |
Why?
| Area Under Curve | 1 | 2019 | 306 | 0.040 |
Why?
| Cells, Cultured | 3 | 2016 | 4087 | 0.040 |
Why?
| Aquaporin 1 | 1 | 2018 | 3 | 0.040 |
Why?
| Radiotherapy | 1 | 2019 | 185 | 0.040 |
Why?
| Mice, Nude | 1 | 2020 | 677 | 0.040 |
Why?
| Stromal Cells | 1 | 2019 | 106 | 0.040 |
Why?
| Pancreatic Elastase | 1 | 2018 | 60 | 0.040 |
Why?
| Cause of Death | 3 | 2005 | 395 | 0.040 |
Why?
| Congresses as Topic | 1 | 2020 | 215 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2021 | 804 | 0.040 |
Why?
| Anastomosis, Roux-en-Y | 2 | 2010 | 27 | 0.040 |
Why?
| Hospitals, High-Volume | 1 | 2018 | 39 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2013 | 1491 | 0.040 |
Why?
| Preoperative Period | 1 | 2018 | 116 | 0.040 |
Why?
| Anastomotic Leak | 1 | 2017 | 39 | 0.030 |
Why?
| Betacoronavirus | 1 | 2020 | 252 | 0.030 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 502 | 0.030 |
Why?
| Patient Safety | 1 | 2020 | 287 | 0.030 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 754 | 0.030 |
Why?
| Robotic Surgical Procedures | 1 | 2019 | 113 | 0.030 |
Why?
| Diabetic Nephropathies | 3 | 2005 | 284 | 0.030 |
Why?
| Intestinal Neoplasms | 1 | 2016 | 28 | 0.030 |
Why?
| Cell Movement | 1 | 2021 | 942 | 0.030 |
Why?
| Drug Therapy, Combination | 3 | 2004 | 1037 | 0.030 |
Why?
| Principal Component Analysis | 1 | 2016 | 190 | 0.030 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 259 | 0.030 |
Why?
| Transplantation, Homologous | 2 | 2010 | 402 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2019 | 717 | 0.030 |
Why?
| Nutritional Status | 1 | 2018 | 328 | 0.030 |
Why?
| Anastomosis, Surgical | 1 | 2016 | 150 | 0.030 |
Why?
| Vitamins | 1 | 2017 | 173 | 0.030 |
Why?
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 98 | 0.030 |
Why?
| Research Design | 1 | 2021 | 1043 | 0.030 |
Why?
| Feces | 1 | 2018 | 442 | 0.030 |
Why?
| Cell Line | 1 | 2021 | 2774 | 0.030 |
Why?
| Animals | 3 | 2022 | 35334 | 0.030 |
Why?
| Anatomy, Cross-Sectional | 1 | 2014 | 10 | 0.030 |
Why?
| Extracellular Matrix | 1 | 2019 | 506 | 0.030 |
Why?
| Radiation Dosage | 1 | 2016 | 154 | 0.030 |
Why?
| Flow Cytometry | 1 | 2018 | 1158 | 0.030 |
Why?
| Intraoperative Care | 1 | 2014 | 46 | 0.030 |
Why?
| Kidney Failure, Chronic | 3 | 2004 | 546 | 0.030 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 85 | 0.030 |
Why?
| Immunologic Memory | 1 | 2016 | 349 | 0.030 |
Why?
| Feasibility Studies | 1 | 2017 | 869 | 0.030 |
Why?
| Biomedical Research | 1 | 2019 | 639 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 2010 | 2013 | 0.030 |
Why?
| Indole Alkaloids | 1 | 2013 | 7 | 0.030 |
Why?
| Antigens, Neoplasm | 1 | 2016 | 308 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2005 | 763 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 1614 | 0.030 |
Why?
| Cytokines | 2 | 2016 | 2018 | 0.030 |
Why?
| Drug Interactions | 2 | 2005 | 397 | 0.030 |
Why?
| Peptic Ulcer | 1 | 2013 | 18 | 0.030 |
Why?
| Histocompatibility Testing | 2 | 2004 | 121 | 0.030 |
Why?
| Asymptomatic Diseases | 1 | 2013 | 84 | 0.020 |
Why?
| Global Health | 1 | 2015 | 328 | 0.020 |
Why?
| Safety | 2 | 2004 | 335 | 0.020 |
Why?
| Postoperative Care | 1 | 2013 | 244 | 0.020 |
Why?
| Pandemics | 1 | 2020 | 1500 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2016 | 1109 | 0.020 |
Why?
| Hypoxia | 1 | 2019 | 1081 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2017 | 1368 | 0.020 |
Why?
| Carcinoma, Renal Cell | 1 | 2013 | 177 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2021 | 1708 | 0.020 |
Why?
| In Situ Hybridization | 1 | 2011 | 296 | 0.020 |
Why?
| Korea | 1 | 2010 | 10 | 0.020 |
Why?
| Cell Growth Processes | 1 | 2010 | 49 | 0.020 |
Why?
| Lung | 1 | 2023 | 3928 | 0.020 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.020 |
Why?
| Microsatellite Repeats | 1 | 2011 | 163 | 0.020 |
Why?
| Odds Ratio | 1 | 2013 | 1018 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2010 | 187 | 0.020 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2010 | 123 | 0.020 |
Why?
| Cardiovascular Diseases | 1 | 2001 | 1997 | 0.020 |
Why?
| Thyroid Neoplasms | 1 | 2013 | 305 | 0.020 |
Why?
| Blood Glucose | 3 | 2004 | 2071 | 0.020 |
Why?
| Edetic Acid | 1 | 2009 | 49 | 0.020 |
Why?
| Pyridoxal Phosphate | 1 | 2009 | 21 | 0.020 |
Why?
| Kidney Neoplasms | 1 | 2013 | 346 | 0.020 |
Why?
| PTEN Phosphohydrolase | 1 | 2010 | 157 | 0.020 |
Why?
| Tetrazolium Salts | 1 | 2008 | 17 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 427 | 0.020 |
Why?
| Thiazoles | 1 | 2008 | 118 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2010 | 527 | 0.020 |
Why?
| Surgical Procedures, Operative | 1 | 2010 | 242 | 0.020 |
Why?
| bcl-2-Associated X Protein | 1 | 2007 | 55 | 0.020 |
Why?
| Glyburide | 1 | 2007 | 32 | 0.020 |
Why?
| Recurrence | 1 | 2010 | 1011 | 0.020 |
Why?
| Epigenesis, Genetic | 1 | 2011 | 617 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2007 | 423 | 0.020 |
Why?
| Deoxycytidine Kinase | 1 | 2006 | 3 | 0.020 |
Why?
| Ribonucleoside Diphosphate Reductase | 1 | 2006 | 5 | 0.020 |
Why?
| Mutation | 1 | 2017 | 3702 | 0.020 |
Why?
| Motorcycles | 1 | 2006 | 6 | 0.020 |
Why?
| Choledochostomy | 1 | 2006 | 11 | 0.020 |
Why?
| Budd-Chiari Syndrome | 1 | 2006 | 5 | 0.020 |
Why?
| Tyrosine | 1 | 2007 | 222 | 0.020 |
Why?
| 5'-Nucleotidase | 1 | 2006 | 39 | 0.020 |
Why?
| Fluorescein Angiography | 1 | 2006 | 142 | 0.020 |
Why?
| Cytidine Deaminase | 1 | 2006 | 57 | 0.020 |
Why?
| Colorectal Neoplasms | 1 | 2013 | 744 | 0.020 |
Why?
| Phosphorylation | 1 | 2010 | 1714 | 0.020 |
Why?
| Prostatic Neoplasms | 1 | 2013 | 995 | 0.020 |
Why?
| Economics, Pharmaceutical | 1 | 2005 | 9 | 0.020 |
Why?
| Antilymphocyte Serum | 1 | 2005 | 63 | 0.020 |
Why?
| Hemorrhage | 1 | 2010 | 680 | 0.010 |
Why?
| Blood Group Incompatibility | 1 | 2005 | 11 | 0.010 |
Why?
| Methylprednisolone | 1 | 2005 | 83 | 0.010 |
Why?
| Fatal Outcome | 1 | 2006 | 300 | 0.010 |
Why?
| Maximum Tolerated Dose | 1 | 2005 | 193 | 0.010 |
Why?
| Proteomics | 1 | 2011 | 1053 | 0.010 |
Why?
| Isoantibodies | 1 | 2005 | 57 | 0.010 |
Why?
| Accidents, Traffic | 1 | 2006 | 184 | 0.010 |
Why?
| Glycerolphosphate Dehydrogenase | 1 | 2004 | 6 | 0.010 |
Why?
| Fructose-Bisphosphate Aldolase | 1 | 2004 | 8 | 0.010 |
Why?
| Glucokinase | 1 | 2004 | 14 | 0.010 |
Why?
| Intraocular Pressure | 1 | 2006 | 299 | 0.010 |
Why?
| DNA Primers | 1 | 2005 | 507 | 0.010 |
Why?
| Visual Acuity | 1 | 2006 | 326 | 0.010 |
Why?
| Pyruvate Kinase | 1 | 2004 | 26 | 0.010 |
Why?
| Renal Circulation | 1 | 2004 | 57 | 0.010 |
Why?
| Diabetic Neuropathies | 1 | 2005 | 94 | 0.010 |
Why?
| Tissue Culture Techniques | 1 | 2004 | 75 | 0.010 |
Why?
| Transcriptional Activation | 1 | 2006 | 366 | 0.010 |
Why?
| Pharmacogenetics | 1 | 2005 | 172 | 0.010 |
Why?
| Tumor Suppressor Proteins | 1 | 2006 | 311 | 0.010 |
Why?
| Carcinoma, Transitional Cell | 1 | 2003 | 59 | 0.010 |
Why?
| Monitoring, Physiologic | 1 | 2005 | 261 | 0.010 |
Why?
| Kidney Function Tests | 1 | 2003 | 152 | 0.010 |
Why?
| Cell Separation | 1 | 2004 | 315 | 0.010 |
Why?
| Respiratory Insufficiency | 1 | 2006 | 312 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2004 | 1091 | 0.010 |
Why?
| Thrombosis | 1 | 2005 | 348 | 0.010 |
Why?
| Base Sequence | 1 | 2005 | 2138 | 0.010 |
Why?
| Obesity, Morbid | 1 | 2005 | 242 | 0.010 |
Why?
| Vulvar Diseases | 1 | 2001 | 9 | 0.010 |
Why?
| Immunoenzyme Techniques | 1 | 2001 | 211 | 0.010 |
Why?
| Gene Expression | 1 | 2006 | 1461 | 0.010 |
Why?
| Glucocorticoids | 1 | 2005 | 583 | 0.010 |
Why?
| Ischemia | 1 | 2004 | 405 | 0.010 |
Why?
| Morphogenesis | 1 | 2001 | 158 | 0.010 |
Why?
| Hemodynamics | 1 | 2004 | 1094 | 0.010 |
Why?
| Neoplasm Proteins | 1 | 2001 | 417 | 0.010 |
Why?
| Blood Pressure | 1 | 2005 | 1735 | 0.010 |
Why?
| T-Lymphocytes | 1 | 2005 | 1935 | 0.010 |
Why?
| Hypoglycemic Agents | 1 | 2005 | 1219 | 0.010 |
Why?
| Body Mass Index | 1 | 2004 | 2269 | 0.010 |
Why?
| Infant, Newborn | 1 | 2001 | 5769 | 0.010 |
Why?
|
|
Del Chiaro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|